JAMA, ISSN 0098-7484, 01/2013, Volume 309, Issue 3, pp. 275 - 282
Bacterial coinfection complicated nearly all influenza deaths in the 1918 influenza pandemic and up to 34% of 2009 pandemic influenza A(H1N1) infections...
UNITED-STATES | MEDICINE, GENERAL & INTERNAL | COMMUNITY-ACQUIRED PNEUMONIA | ADVISORY-COMMITTEE | STREPTOCOCCUS-PNEUMONIAE | VIRUS | RESPIRATORY-TRACT COMPLICATIONS | PANDEMIC INFLUENZA | STAPHYLOCOCCUS-AUREUS | GLOBAL MORTALITY | H1N1 INFLUENZA | Community-Acquired Infections - diagnosis | Influenza Vaccines - administration & dosage | Coinfection | Humans | Middle Aged | Critical Illness | Male | Influenza, Human - complications | Staphylococcal Infections - complications | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Pneumonia, Bacterial - mortality | Fatal Outcome | Influenza A Virus, H1N1 Subtype | Influenza, Human - mortality | Influenza, Human - diagnosis | Community-Acquired Infections - complications | Influenza, Human - therapy | Community-Acquired Infections - mortality | Staphylococcal Infections - drug therapy | Pneumonia, Bacterial - complications | Pneumonia, Bacterial - diagnosis | Morbidity | Staphylococcal Infections - mortality | Staphylococcal Infections - diagnosis | Critical Care | Pneumonia, Bacterial - drug therapy | Staphylococcus infections | Systematic review | Immunization | Pandemics | Swine flu
UNITED-STATES | MEDICINE, GENERAL & INTERNAL | COMMUNITY-ACQUIRED PNEUMONIA | ADVISORY-COMMITTEE | STREPTOCOCCUS-PNEUMONIAE | VIRUS | RESPIRATORY-TRACT COMPLICATIONS | PANDEMIC INFLUENZA | STAPHYLOCOCCUS-AUREUS | GLOBAL MORTALITY | H1N1 INFLUENZA | Community-Acquired Infections - diagnosis | Influenza Vaccines - administration & dosage | Coinfection | Humans | Middle Aged | Critical Illness | Male | Influenza, Human - complications | Staphylococcal Infections - complications | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Pneumonia, Bacterial - mortality | Fatal Outcome | Influenza A Virus, H1N1 Subtype | Influenza, Human - mortality | Influenza, Human - diagnosis | Community-Acquired Infections - complications | Influenza, Human - therapy | Community-Acquired Infections - mortality | Staphylococcal Infections - drug therapy | Pneumonia, Bacterial - complications | Pneumonia, Bacterial - diagnosis | Morbidity | Staphylococcal Infections - mortality | Staphylococcal Infections - diagnosis | Critical Care | Pneumonia, Bacterial - drug therapy | Staphylococcus infections | Systematic review | Immunization | Pandemics | Swine flu
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 5/2010, Volume 50, Issue 9, pp. 1252 - 1255
Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the...
H1N1 subtype influenza A virus | Pandemics | Infectious diseases | Influenza A virus | Antivirals | Viruses | Infections | Immunocompromised hosts | Inhibitory concentration 50 | Genetic mutation | BRIEF REPORTS
H1N1 subtype influenza A virus | Pandemics | Infectious diseases | Influenza A virus | Antivirals | Viruses | Infections | Immunocompromised hosts | Inhibitory concentration 50 | Genetic mutation | BRIEF REPORTS
Journal Article
mBio, ISSN 2161-2129, 04/2016, Volume 7, Issue 2, p. e00417
Despite long-term investment, influenza continues to be a significant worldwide problem. The cornerstone of protection remains vaccination, and approved...
NEURAMINIDASE | IMMUNITY | EFFICACY | TITERS | RESISTANCE | MICROBIOLOGY | PANDEMIC H1N1 | INFECTION | SERUM | REPRODUCIBILITY | VACCINES | Influenza A Virus, H1N1 Subtype - immunology | Influenza Vaccines - administration & dosage | United States | Humans | Middle Aged | Vaccination | Influenza A Virus, H1N1 Subtype - physiology | Male | Hemagglutinin Glycoproteins, Influenza Virus - immunology | Healthy Volunteers | Neuraminidase - immunology | Young Adult | Influenza Vaccines - immunology | Adolescent | Adult | Antibodies, Viral - immunology | Female | Influenza, Human - virology | Influenza, Human - prevention & control | Influenza, Human - immunology
NEURAMINIDASE | IMMUNITY | EFFICACY | TITERS | RESISTANCE | MICROBIOLOGY | PANDEMIC H1N1 | INFECTION | SERUM | REPRODUCIBILITY | VACCINES | Influenza A Virus, H1N1 Subtype - immunology | Influenza Vaccines - administration & dosage | United States | Humans | Middle Aged | Vaccination | Influenza A Virus, H1N1 Subtype - physiology | Male | Hemagglutinin Glycoproteins, Influenza Virus - immunology | Healthy Volunteers | Neuraminidase - immunology | Young Adult | Influenza Vaccines - immunology | Adolescent | Adult | Antibodies, Viral - immunology | Female | Influenza, Human - virology | Influenza, Human - prevention & control | Influenza, Human - immunology
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2018, Volume 62, Issue 1
Journal Article
mBio, ISSN 2161-2129, 01/2018, Volume 9, Issue 1, p. e02284-17
Influenza virus hemagglutinin (HA) surface glycoprotein is currently the primary target of licensed influenza vaccines. Recently, broadly reactive antibodies...
Antibody | CHIM | Influenza | Universal vaccine | HA stalk | Neuraminidase | Human challenge | Influenza A | influenza | antibody | influenza A | FLU-PRO | HUMANS | MICROBIOLOGY | INDUCTION | STEM | INSTRUMENT | universal vaccine | neuraminidase | human challenge | INFECTION | VACCINES | Influenza A Virus, H1N1 Subtype - immunology | Influenza, Human - pathology | Enzyme-Linked Immunosorbent Assay | Humans | Middle Aged | Male | Virus Shedding | Hemagglutinin Glycoproteins, Influenza Virus - immunology | Healthy Volunteers | Antibodies, Viral - blood | Hemagglutination Inhibition Tests | Young Adult | Adolescent | Adult | Female | Child | Influenza, Human - prevention & control
Antibody | CHIM | Influenza | Universal vaccine | HA stalk | Neuraminidase | Human challenge | Influenza A | influenza | antibody | influenza A | FLU-PRO | HUMANS | MICROBIOLOGY | INDUCTION | STEM | INSTRUMENT | universal vaccine | neuraminidase | human challenge | INFECTION | VACCINES | Influenza A Virus, H1N1 Subtype - immunology | Influenza, Human - pathology | Enzyme-Linked Immunosorbent Assay | Humans | Middle Aged | Male | Virus Shedding | Hemagglutinin Glycoproteins, Influenza Virus - immunology | Healthy Volunteers | Antibodies, Viral - blood | Hemagglutination Inhibition Tests | Young Adult | Adolescent | Adult | Female | Child | Influenza, Human - prevention & control
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 2/2011, Volume 203, Issue 3, pp. 348 - 357
Background. The 2009 influenza A(H1N1) pandemic called attention to the limited influenza treatment options available, especially in individuals at high risk...
H1N1 subtype influenza A virus | Pulmonary alveoli | Inoculation | Pandemics | Disease transmission | Lungs | Influenza A virus | Antivirals | Weight loss | Viruses | UNITED-STATES | INFECTIOUS DISEASES | ADAMANTANE RESISTANCE | MICROBIOLOGY | IMMUNOLOGY | H1N1 VIRUS | OSELTAMIVIR | NEURAMINIDASE | IN-VITRO | A/H3N2 VIRUS | A VIRUSES | RAPID SELECTION | ISOLATED WORLDWIDE | Antiviral Agents - pharmacology | Global Health | Orthomyxoviridae Infections - veterinary | Humans | Influenza A Virus, H1N1 Subtype - pathogenicity | Influenza, Human - epidemiology | Male | Virus Shedding | Drug Resistance, Multiple, Viral | Ferrets | Influenza A Virus, H1N1 Subtype - drug effects | Lung - virology | Animals | Orthomyxoviridae Infections - transmission | Influenza, Human - virology | Orthomyxoviridae Infections - virology | Major and Brief Reports
H1N1 subtype influenza A virus | Pulmonary alveoli | Inoculation | Pandemics | Disease transmission | Lungs | Influenza A virus | Antivirals | Weight loss | Viruses | UNITED-STATES | INFECTIOUS DISEASES | ADAMANTANE RESISTANCE | MICROBIOLOGY | IMMUNOLOGY | H1N1 VIRUS | OSELTAMIVIR | NEURAMINIDASE | IN-VITRO | A/H3N2 VIRUS | A VIRUSES | RAPID SELECTION | ISOLATED WORLDWIDE | Antiviral Agents - pharmacology | Global Health | Orthomyxoviridae Infections - veterinary | Humans | Influenza A Virus, H1N1 Subtype - pathogenicity | Influenza, Human - epidemiology | Male | Virus Shedding | Drug Resistance, Multiple, Viral | Ferrets | Influenza A Virus, H1N1 Subtype - drug effects | Lung - virology | Animals | Orthomyxoviridae Infections - transmission | Influenza, Human - virology | Orthomyxoviridae Infections - virology | Major and Brief Reports
Journal Article
Critical Care Medicine, ISSN 0090-3493, 02/2015, Volume 43, Issue 2, pp. 487 - 488
Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 07/2018, Volume 18, Issue 1, pp. 353 - 9
Background: In clinical studies involving a healthy volunteer human challenge model, a valid and reliable measure to assess the evolution of patient-reported...
Virus | Human challenge study | Influenza | Symptoms | influenza | NEURAMINIDASE | INFECTIOUS DISEASES | ANTIBODY | Economic aspects | Patient outcomes | Hospital care | Analysis | Medical care, Cost of
Virus | Human challenge study | Influenza | Symptoms | influenza | NEURAMINIDASE | INFECTIOUS DISEASES | ANTIBODY | Economic aspects | Patient outcomes | Hospital care | Analysis | Medical care, Cost of
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2010, Volume 50, Issue 9, p. 1252
Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the...
Pandemics | Infectious diseases | Inhibitor drugs | Swine flu | Mutation | Drug resistance | Drug therapy | Antiviral drugs
Pandemics | Infectious diseases | Inhibitor drugs | Swine flu | Mutation | Drug resistance | Drug therapy | Antiviral drugs
Journal Article
Critical Care Medicine, ISSN 0090-3493, 04/2011, Volume 39, Issue 4, pp. 926 - 927
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2018, Volume 13, Issue 3, p. e0194180
The inFLUenza Patient Reported Outcome (FLU-PRO) measure is a daily diary assessing signs/symptoms of influenza across six body systems: Nose, Throat, Eyes,...
Influenza, Human - pathology | Prospective Studies | Humans | Middle Aged | Self Report | Medical Records | Aged, 80 and over | Adult | Female | Male | Aged | Influenza, Human - physiopathology | Evaluation | Care and treatment | Influenza | Medical care | Diagnosis | Health status indicators | Quality management | Military medicine | Correlation coefficients | Viruses | Preventive medicine | Patients | Pharynx | Disease control | Disease prevention | Infectious diseases | Illnesses | Reproducibility | Correlation analysis | Nose | Reliability analysis | Product development | Adults
Influenza, Human - pathology | Prospective Studies | Humans | Middle Aged | Self Report | Medical Records | Aged, 80 and over | Adult | Female | Male | Aged | Influenza, Human - physiopathology | Evaluation | Care and treatment | Influenza | Medical care | Diagnosis | Health status indicators | Quality management | Military medicine | Correlation coefficients | Viruses | Preventive medicine | Patients | Pharynx | Disease control | Disease prevention | Infectious diseases | Illnesses | Reproducibility | Correlation analysis | Nose | Reliability analysis | Product development | Adults
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 5/2010, Volume 201, Issue 9, pp. 1397 - 1403
Background. The overall impact of influenza virus infection in immunocompromised patients is largely unknown. Antigenic drift and genetic variations during...
Pandemics | Influenza A virus | Antivirals | Viruses | Orthomyxoviridae | Infections | Immunocompromised hosts | Inhibitory concentration 50 | Genetic mutation | H3N2 subtype influenza A virus | MORTALITY | INFECTIOUS DISEASES | SWAB | SEASONAL INFLUENZA | SURVEILLANCE | ADULTS | MICROBIOLOGY | IMMUNOLOGY | OUTBREAK | H1N1 | OSELTAMIVIR | Lymphoma, Mantle-Cell - complications | Drug Resistance, Multiple, Viral - genetics | Influenza A Virus, H3N2 Subtype - drug effects | Virus Replication - genetics | Humans | Molecular Sequence Data | Male | Influenza A Virus, H3N2 Subtype - genetics | Influenza, Human - transmission | Reverse Transcriptase Polymerase Chain Reaction | Lymphoma, Mantle-Cell - virology | Ferrets - virology | Animals | Orthomyxoviridae Infections - transmission | Adult | Influenza, Human - virology | Immunocompromised Host | Influenza, Human - drug therapy | Orthomyxoviridae Infections - virology | Influenza, Human - immunology | Influenza viruses | Immunocompromised host | Genetic variation | Analysis | Genetic aspects | Research | Health aspects
Pandemics | Influenza A virus | Antivirals | Viruses | Orthomyxoviridae | Infections | Immunocompromised hosts | Inhibitory concentration 50 | Genetic mutation | H3N2 subtype influenza A virus | MORTALITY | INFECTIOUS DISEASES | SWAB | SEASONAL INFLUENZA | SURVEILLANCE | ADULTS | MICROBIOLOGY | IMMUNOLOGY | OUTBREAK | H1N1 | OSELTAMIVIR | Lymphoma, Mantle-Cell - complications | Drug Resistance, Multiple, Viral - genetics | Influenza A Virus, H3N2 Subtype - drug effects | Virus Replication - genetics | Humans | Molecular Sequence Data | Male | Influenza A Virus, H3N2 Subtype - genetics | Influenza, Human - transmission | Reverse Transcriptase Polymerase Chain Reaction | Lymphoma, Mantle-Cell - virology | Ferrets - virology | Animals | Orthomyxoviridae Infections - transmission | Adult | Influenza, Human - virology | Immunocompromised Host | Influenza, Human - drug therapy | Orthomyxoviridae Infections - virology | Influenza, Human - immunology | Influenza viruses | Immunocompromised host | Genetic variation | Analysis | Genetic aspects | Research | Health aspects
Journal Article
Critical Care Medicine, ISSN 0090-3493, 04/2011, Volume 39, Issue 4, pp. 926 - 927
Journal Article
MBIO, ISSN 2150-7511, 03/2019, Volume 10, Issue 2, p. e00307-19
The effectiveness of influenza vaccines against circulating A(H1N1) pdm09 viruses was modest for several seasons despite the absence of antigenic drift of...
influenza | IMMUNITY | ASSAY | vaccines | VACCINE | HUMANS | MICROBIOLOGY | PANDEMIC H1N1 | SERUM | neuraminidase | antigenic drift | RESISTANCE | INFECTION | MONOCLONAL-ANTIBODIES | monoclonal antibodies | EPITOPES
influenza | IMMUNITY | ASSAY | vaccines | VACCINE | HUMANS | MICROBIOLOGY | PANDEMIC H1N1 | SERUM | neuraminidase | antigenic drift | RESISTANCE | INFECTION | MONOCLONAL-ANTIBODIES | monoclonal antibodies | EPITOPES
Journal Article
Critical Care Medicine, ISSN 0090-3493, 10/2010, Volume 38, Issue 10, pp. 2081 - 2082
Journal Article
16.
Full Text
IgG antibodies to dengue enhanced for Fc[gamma]RIIIA binding determine disease severity
Science, ISSN 0036-8075, 01/2017, Volume 355, Issue 6323, p. 395
In some cases, secondary infections of dengue virus can be extremely serious and result in plasma leakage, thrombocytopenia, and hemorrhagic disease. This...
Immunoglobulins | Dengue hemorrhagic fever | Health aspects | Risk factors | Antigens | Dengue fever | Immunoglobulin G | Dengue | Viral diseases | Antibodies | Viruses | Infections | Vaccines | Patients | Fever | Fc receptors | Receptors | Immunology | Neutralizing | Extreme values
Immunoglobulins | Dengue hemorrhagic fever | Health aspects | Risk factors | Antigens | Dengue fever | Immunoglobulin G | Dengue | Viral diseases | Antibodies | Viruses | Infections | Vaccines | Patients | Fever | Fc receptors | Receptors | Immunology | Neutralizing | Extreme values
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 10/2009, Volume 200, Issue 8, pp. 1232 - 1241
Background. Examination of the evolutionary dynamics of complete influenza viral genomes reveals that other processes, in conjunction with antigenic drift,...
Pathology | Lungs | Influenza A virus | Viruses | Evolution | Amino acids | Orthomyxoviridae | Genetic mutation | H3N2 subtype influenza A virus | Human influenza | INFECTIOUS DISEASES | H3N2 VIRUSES | A VIRUSES | GENOME | REVEALS | Cell Line | Genetic Drift | Lung - pathology | Humans | Orthomyxoviridae Infections - pathology | Selection, Genetic | Antigens, Viral - genetics | Influenza, Human - epidemiology | Male | Influenza A Virus, H3N2 Subtype - genetics | Phylogeny | Ferrets | Animals | Virus Replication | Dogs | Influenza, Human - virology | Orthomyxoviridae Infections - virology | Antigens | Prognosis | Gene mutations | Influenza | Physiological aspects | Genetic aspects | Research
Pathology | Lungs | Influenza A virus | Viruses | Evolution | Amino acids | Orthomyxoviridae | Genetic mutation | H3N2 subtype influenza A virus | Human influenza | INFECTIOUS DISEASES | H3N2 VIRUSES | A VIRUSES | GENOME | REVEALS | Cell Line | Genetic Drift | Lung - pathology | Humans | Orthomyxoviridae Infections - pathology | Selection, Genetic | Antigens, Viral - genetics | Influenza, Human - epidemiology | Male | Influenza A Virus, H3N2 Subtype - genetics | Phylogeny | Ferrets | Animals | Virus Replication | Dogs | Influenza, Human - virology | Orthomyxoviridae Infections - virology | Antigens | Prognosis | Gene mutations | Influenza | Physiological aspects | Genetic aspects | Research
Journal Article
MBIO, ISSN 2150-7511, 05/2019, Volume 10, Issue 3, p. e00760-19
In this study, we examined the relationships between anti-influenza virus serum antibody titers, clinical disease, and peripheral blood leukocyte (PBL) global...
IMMUNITY | antibody | PROTECTION | SIGNATURES | DISTINCT | HA stalk antibodies | MICROBIOLOGY | MECHANISMS | INDUCTION | NEURAMINIDASE | PANTHER | HA head antibodies | NA antibodies | T-CELLS | DURATION | host response | influenza | antibody function | immune response | human challenge | immune markers | regulation of gene expression | genomics | microarrays
IMMUNITY | antibody | PROTECTION | SIGNATURES | DISTINCT | HA stalk antibodies | MICROBIOLOGY | MECHANISMS | INDUCTION | NEURAMINIDASE | PANTHER | HA head antibodies | NA antibodies | T-CELLS | DURATION | host response | influenza | antibody function | immune response | human challenge | immune markers | regulation of gene expression | genomics | microarrays
Journal Article
JAMA, The Journal of the American Medical Association, ISSN 0098-7484, 01/2013, Volume 309, Issue 3, p. 275
The article discusses the case of a 58-year-old man presented with fever, cough, myalgias and shortness of breath for 5 days to arrive at a better...
Care and treatment | Medical case management | Comorbidity | Risk factors | Case studies | Host-bacteria relationships | Control | Influenza | Bacteria, Pathogenic | Causes of | Diagnosis | Health aspects | Methods
Care and treatment | Medical case management | Comorbidity | Risk factors | Case studies | Host-bacteria relationships | Control | Influenza | Bacteria, Pathogenic | Causes of | Diagnosis | Health aspects | Methods
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2014, Volume 58, Issue 2, pp. 214 - 224
Severely immunocompromised individuals infected with influenza are different from the influenza infected that are nonimmunocompromised. Issues to consider...
Influenza A | Stem cell transplant | Immunocompromised host | Influenza | influenza | MORTALITY | INFECTIOUS DISEASES | stem cell transplant | influenza A | IMMUNODEFICIENCY-VIRUS-INFECTION | HEMATOPOIETIC STEM-CELL | MICROBIOLOGY | IMMUNOLOGY | RECIPIENTS | PNEUMONIA | SOLID-ORGAN TRANSPLANT | H1N1 VIRUS | THERAPY | COMMUNITY | RAPID SELECTION | immunocompromised host | Influenza, Human - pathology | Prospective Studies | Cytokines - analysis | Humans | Middle Aged | Male | Virus Shedding | Patient Outcome Assessment | Serum - immunology | Young Adult | Nasal Mucosa - immunology | Adolescent | Adult | Female | Aged | Immunocompromised Host | Cytokines - blood | Influenza, Human - immunology | Complications and side effects | Evaluation | Immunosuppression | Outcome and process assessment (Health Care) | Diagnosis | Risk factors | and Commentaries
Influenza A | Stem cell transplant | Immunocompromised host | Influenza | influenza | MORTALITY | INFECTIOUS DISEASES | stem cell transplant | influenza A | IMMUNODEFICIENCY-VIRUS-INFECTION | HEMATOPOIETIC STEM-CELL | MICROBIOLOGY | IMMUNOLOGY | RECIPIENTS | PNEUMONIA | SOLID-ORGAN TRANSPLANT | H1N1 VIRUS | THERAPY | COMMUNITY | RAPID SELECTION | immunocompromised host | Influenza, Human - pathology | Prospective Studies | Cytokines - analysis | Humans | Middle Aged | Male | Virus Shedding | Patient Outcome Assessment | Serum - immunology | Young Adult | Nasal Mucosa - immunology | Adolescent | Adult | Female | Aged | Immunocompromised Host | Cytokines - blood | Influenza, Human - immunology | Complications and side effects | Evaluation | Immunosuppression | Outcome and process assessment (Health Care) | Diagnosis | Risk factors | and Commentaries
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.